Akari Therapeutics publishes 2025 annual report

Akari Therapeutics Plc Sponsored ADR

AKTX

0.00

Akari Therapeutics published its annual report for the year ended Dec. 31, 2025, pivoting to next-generation antibody-drug conjugates built on proprietary payload toxins.
AKTX-101 remained the lead program in preclinical development, targeting Trop2 across multiple solid tumor types.
Legacy programs nomacopan and PAS-nomacopan stayed paused for internal development, with partnering pursued to advance them externally.
PHP-303 also shifted to an external partnering strategy, with impairment tied to reprioritization and lack of a partner.
Going-concern uncertainty flagged, with management pursuing additional funding via financings or strategic collaborations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.